Of the 544 patients studied, 221 had MDR-TB.
在研究的544名患者中，有221人患有耐多药结核。
Q: What concerns you about fighting MDR-TB in the future?
问：你对与耐多药结核病作斗争的前途有什么看法？
Each one lacked a gene coding for a particular MDR protein.
每种酵母缺乏一种特定的MDR蛋白基因。
By July, health workers were treating the first MDR-TB patients.
7月，卫生工作者治疗第一批耐多药结核病患者。
In the United States, 4% of MDR-TB cases met the criteria for XDR-TB.
在美国，4%的耐多药结核病例符合广泛耐药结核的标准。
MDR was a targeted antigen in drug resistance AML.
MDR也是耐药白血病治疗的较好靶抗原。
Verapamil and erythromycin could reverse the MDR of leukemic cells.
异搏定和红霉素对白血病细胞MDR有逆转作用。
MDR-TB is a form of TB that fails to respond to standard first-line drugs.
耐多药结核病是一种对一线标准药物没有反应的结核病形式。
Tuberculosis programmes face tremendous challenges in reducing MDR-TB rates.
结核病规划在减少耐多药结核病发病率方面面临着巨大挑战。
This was 8.5% of the estimated global total of smear-positive cases of MDR-TB.
这仅相当于痰涂阳性耐多药结核病例全球估计总数的8.5%。
Almost 50% of MDR-TB cases worldwide are estimated to occur in China and India.
估计全世界将近50%的耐多药结核病例发生在中国和印度。
There were an estimated 0.5 million cases of multidrug-resistant TB (MDR-TB) in 2007.
2007年，耐多药结核病例估计数为50万例。
There were an estimated 0.5 million cases of multidrug-resistant TB (MDR-TB) in 2006.
在2006年，估计有50万例耐多药结核病例。
This is equivalent to 1% of the estimated global total of smear-positive cases of MDR-TB.
这相当于痰涂阳性的耐多药结核病例全球估计总数的1%。
We also recognize that MDR-TB case Numbers are high, and that we expect more XDR-TB cases.
我们也认识到耐多药结核病例数目甚高，而且我们预计会出现更多的广泛耐药结核病例。
WHO estimates there will be more than 2 million new cases of MDR-TB between 2011 and 2015.
世卫组织估计，2011年至2015年之间将有200多万耐多药结核病新发病例。
QA documents that have been issued to the customer for approval e. g. : ITP, MDR Index etc.
已经发放给客户审批的质量保证文件，例如ITP，MDR索引等。
A second way of developing MDR-TB or XDR-TB is when a patient's own TB develops resistance.
形成耐多药结核或广泛耐药结核的第二个途径是患者自身的结核产生耐药性。
QA documents that have been returned by the customer fully approved e. g. : ITP, MDR Index etc.
由客户完全认可，并退还的质量保证文件，例如，ITP,MDR索引等。
Wherever second-line drugs to treat MDR-TB are being misused, the possibility of XDR-TB exists.
在治疗耐多药结核的二线药物被滥用的任何地方，存在着广泛耐药结核的可能性。
Currently, less than 5% of the estimated MDR-TB cases are being detected by national TB programmes.
目前，经国家结核病规划所查明的病例在估计的耐多药结核病例中所占比例不足5%。
Of the US$ 1 billion gap reported by countries for 2012, US$ 200 million is for the MDR-TB response.
各国报告2012年存在的10亿美元资金短缺中，有两亿美元用在耐多药结核病方面。
Q: Aside from money, what has been the most important factor in running a MDR-TB treatment programme?
问：除了钱外，什么是开展耐多药结核病治疗规划的最重要因素？
"In the 1980s the common wisdom was that MDR-TB was impossible to diagnose and treat," says Jaramillo.
“上世纪八十年代，普遍认为耐多药结核病不可能得到诊断和治疗，”Jaramillo说。
The 2009 WHO TB Report estimated that more than half a million new cases of MDR-TB occurred during 2007.
2009年世卫组织结核病报告估计，在2007年期间耐多药结核病新发病例为50多万例。
MDR-TB takes longer to treat with second-line drugs, which are more expensive and have more side-effects.
用二线药物治疗耐多药结核所需时间更长，更加昂贵，并且产生更多副作用。
In Latvia, a country with one of the highest rates of MDR-TB, 19% of MDR-TB cases met the XDR-TB criteria.
在耐多药结核发生率最高之一的国家拉脱维亚，19%的耐多药结核病例符合广泛耐药结核的标准。
Only a few months after finishing his six-month treatment, Gagarin became sick again – this time with MDR-TB.
6个月疗程结束后的仅数月内，他再次病倒，这次是耐多药结核病。
A total of 23 353 cases of MDR-TB were notified in 2006, of which just over half were in the European Region.
在2006年总共通报了23 353起耐多药结核病例，欧洲区域占其中一半以上。
A total of 23 353 cases of MDR-TB were notified in 2006, of which just over half were in the European Region.
在2006年总共通报了23 353起耐多药结核病例，欧洲区域占其中一半以上。
应用推荐